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EDITORIALDisruption of HBx-DDB1 by NTZ: New Mechanistic Insight Into an
Old Drug With Broad Anti-infective Activitiesepatitis B virus (HBV) infection leads to chronicHhepatitis B (CHB) in approximately 250 million
people worldwide, putting them at high risk for developing
cirrhosis and hepatocellular carcinoma. HBV is a partially
double-stranded DNA virus that belongs to the Hepadnavir-
idae family. After entry into host cells, the viral genome is
transported into the nucleus and converted to a covalently
closed circular DNA (cccDNA), which serves as the tem-
plate for all HBV viral RNAs. Currently available HBV
antiviral drugs inhibit the reverse transcription of HBV
pregenomic RNA but fail to suppress the established
cccDNA reservoir in infected hepatocytes, resulting in viral
rebound after therapy. In addition, HBV surface antigen
hepatitis B surface antigen expressed from the cccDNA
maintains immune tolerance to prevent induction of anti-
bodies to hepatitis B surface antigen, which are critical for
a functional cure of CHB in patients.
The HBV regulatory protein hepatitis B virus X protein
(HBx) is critical for HBV gene expression from the
episomal cccDNA template via its interaction with cellular
proteins. The best-characterized HBx binding partner is
the damage-specific DNA binding protein 1 (DDB1). This
binding is essential for HBx-enhanced HBV replication. The
DNA repair factor DDB1 functions as a linker protein for
the assembly of a number of Cullin 4-ROC1/RING E3
ubiquitin ligase. DDB1 bridges CUL4 to individual DDB1-
binding WD40 proteins (or DDB Cullin-associated fac-
tors), which in turn recruit substrates to the CUL4–ROC1
catalytic core for subsequent ubiquitination and degrada-
tion. A structural study has shown that HBx contains an
H-box that is shared by several DDB1-binding WD40
proteins and directly binds to DDB1,1 suggesting that
HBx functions as a DDB Cullin-associated factor to retarget
the DDB1–Cullin 4-ROC1/RING E3 ubiquitin ligase to a
new host factor. Two recent reports have shown that
the HBx-DDB1-CUL4-ROC1 E3 ligase complex binds and
degrades the structural maintenance of chromosomes
(SMC) complex proteins SMC5/6 to enhance HBV
replication.2,3
It is clear that disruption of the HBx/DDB1 interaction
provides a strategy to develop novel therapeutics that
inhibit HBV cccDNA activity. However, multiple efforts
have failed to identify viable small molecules that can effi-
ciently disrupt the interaction in vivo. Sekiba et al4 devel-
oped an elegant high-throughput screening assay to
efficiently identify inhibitors of the HBx/DDB1 interaction.
A novel split luciferase assay based on HBx–DDB1 interac-
tion was used for screening compounds. The investigatorsCellureported that nitazoxanide (NTZ), a thiazolide anti-infective
agent that has been approved by the Food and Drug
Administration for treating multiple viruses and parasites,
efficiently inhibits the HBx–DDB1 protein interaction.
Consistently, NTZ significantly prevents HBx-induced
SMC5 protein degradation and suppresses HBx-dependent
HBV cccDNA gene expression. Importantly, NTZ also
inhibits HBV replication in human primary hepatocytes
infected with HBV.
These results indicate that NTZ inhibits HBV cccDNA
activity and may provide a new therapeutic agent with the
potential for a functional cure for CHB. In combination with
current anti-HBV inhibitors nucleos(t)ide analogs/reverse
transcriptase inhibitors in CHB patients, it may achieve in-
hibition of HBV gene expression from the NUC-resistant
cccDNA. The clearance of hepatitis B surface antigen in
CHB may reverse its associated immune tolerance and help
to induce antibodies to hepatitis B surface antigen for a
functional cure.
One major limitation of current HBV therapies is the
inability to target cccDNA. HBx has evolved to bind
DDB1 and counteract SMC5/6 activity to facilitate HBV
replication. It will be important to determine how NTZ
inhibits HBx/DDB1 interaction. The reported NZT activity
in suppressing HBV replication, however, is relatively
moderate. It will require further optimization to develop
into a clinically efficacious anti-HBV drug. NZT originally
was discovered in the 1980s and is used for treating
various helminthic and protozoal infections; and it also is
effective in treating a number of viral infections. The
antiprotozoal activity of NZT is believed to be owing to
interference with the pyruvate-ferredoxin oxidoreductase
enzyme-dependent electron transfer reaction, which is
essential to anaerobic energy metabolism. It will be of
interest to determine whether NTZ inhibits other viruses
via similar DDB1-related mechanisms, including viruses
with episomal DNA genomes.
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